ABSTRACT. This retrospective study covers 496 cases of primary amenorrhea (n = 60), secondary amenorrhea (n = 298), and anovulatory oligomenorrhea (n = 138). The test system for these patients included the determination of basal plasma PRL values, the TRH-test (200 IJg TRH i v), LHRH-test (251Jg LHRH i v ), antero-posterior and lateral X-ray of the sella, tomography in cases of suspected pituitary tumor and exclusion of other endocrine dysfunctions. In primary amenorrhea, PRL was found generally low at concentrations of10.6±5.8 ng/ml (mean ±SD) with two exceptions. 230 women with secondary amenorrhea showed normal basal PRL levels (10 ± 5.7 ng/ml), hyperprolactinemia was found in 68 women (23%). From thisgroup,25 patients (37%) had radiological indications of a pituitary tumor. In these patients, basal PRL levels (mean = 366 ng/ml) were significantly higher than in patients with normal sella findings (mean=92.5 ng/ml, p< 0.005). Hyperprolactinemia was detected in 26 women (19%) with anovulatory oligomenorrhea, but in a significantly lower range than in amenorrhea (p < 0.001). Galactorrhea was found in thirteen women (50%) with milk-leakage in two of them. The TRH-induced PRL release was not discriminative for the diagnosis of prolactinoma. The gonadotropic response after LHRH stimulation evaluated either by comparison to early follicular phase conditions or by the standardized Human-Pituitary-Gonadotropin (HPG)-Index score showed a significantly higner frequency of "impaired" responses and R 0, R 1 respectively in cases of pituitary tumors and when PRL exceeded 200 ng/ml.
INTRODUCTION
The hyperprolactinemic status as a topic of intense investigation is describing the cause of various endocrine dysfunctions of the menstrual cycle, e.g. amenorrhea (1-11) and hypogonadism (12, 13) . Several reports have been published about the coincidence of hyperprolactinemia (11-33%) and pituitary tumors (4-9%) among secondary amenorrheic women (1-3, 5, 7, 9, 11) . However, only little information is available about incidence and significance of elevated PRL levels in other anovulatory status such as oligomenorrhea. In this retrospective study, the incidence of hyperprolactinemia, galactorrhea and pituitary tumors is investigated among 496 women showing various disorders of the menstrual cycle: primary and secondary amenorrhea and oligomenorrhea. Clinical and endocrine features are listed and compared to normally menstruating women. In cases of hyperprolactinemia the clinical values of several diagnostic procedures such as radiological examination of the pituitary fossa and dynamic endocrine tests of the pituitary function are outlined. 
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MATERIALS AND METHODS
During the years covered by this study (1975 through 1978) , 496 women were registered by the endocrinological outpatient care of the clinic because of various disorders of the menstrual cycle.
-60 women (mean age 20 years) suffered from primary amenorrhea with ttie following diagnosis: primary ovarian dysgenesis (n = 4), Turner-Syndrome (n = 3), delayed puberty syndrome ( n = 1 0), hypoplasia of the ovary (n = 9), testicular feminization (n = 4), hypothalamic amenorrhea (n = 26), vaginal. aplasia (n = 4); -298 women (age 17-39 years) suffered from secondary amenorrhea for a period of time ranging from four months to 1 7 years; -138 women (age 18-40 years) showed oligomenorrhea and anovulation with cycles between 55 to 90 days, anovulation was confirmed by monophasic SST chart and by measurements of plasma progesterone concentrations.
-50 normally cycling women (mean age 23 years) served as controls: 20 were tested during the early follicular phase and 30 during the laUer part of the menstrual cycle. Human PRL was measured by a double-anti bodyradioimmunoassay: locally prepared PRL preparations free of growth hormone and calibrated against the PBL-preparation F 3 (kindly supplied by the National I nstitute of Health, Bethesda, MO) and F 3 were used as standards. The hormone preparation F 3 was used for the labelling with 125-iodine by the lactoperoxidasemethod. Antiserum against human PRL was kindly provided by Dr. K. von Werder (Department of Internal Medicine, University of Munich). The incubation was performed at + 4 C for 48 hours and after addition of the second antibody for another 24 hours. The antigenantibody-complex was sedimented by centrifugation (20 min at 2,000 g) and the supernatant decanted. In this assay the intraassay variation was 6% and the interassay variation 16 % . Plasma PRL levels below 30 ng/ml were considered as normal.
The material for the radioimmunoassay of LH and FSH was purchased from Serono (Freiburg, Germany). The standards were calibrated against the preparation LER 907 (provided by the National Institute of Health, Bethesda, Maryland, USA). After incubation for 18 hours at room temperature, free and bound hormone were separated after addition of bovine gamma globulin as a carrier by polyethyleneglycole precipitation. Extragonadal endocrine dysfunctions were excluded by determination of the plasma androgen concentration (dehydroepiandrosterone, androstenedione, testosterone). In cases of hyperprolactinemia, lateral and anterior-posterior X-rays of the sella with visual field examination were performed. Poly tomographies of the sella were done in cases when the sella was found radiologicallyabnormal (enlarged over 124 mm2, asymmetric, double contours, blistering floor) and/ or when the basal PRL levels exceeded 200 ng/ml.
RESULTS
Prolactin
The control group of normally menstruating women (n = 50) showed mean basal plasma PRL levels of 13.1 ± 6.6 ng/ml (mean ± SO). After injection of 200 pg TRH, the mean net increase of PRL was 123 ± 37 ng/ml. In 20 women tested during the early follicular phase (between day 4-6), the mean basal PRL- 
